Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product

Company Milestone - Accuray Incorporated announced the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System at Shandong Cancer Hospital and Institute, marking a significant milestone for the company in addressing the underserved Chinese radiation therapy market [1] - The Tomo C System, developed through the CNNC-Accuray joint venture, has expanded clinical capabilities and enabled potentially curative treatment for more cancer patients in China [1] Market Opportunity - The number of new cancer cases in China is expected to increase by 47% to 7.1 million in 2045, up from 4.8 million in 2022, highlighting the growing demand for advanced radiotherapy technology [2] - The Tomo C System is designed to meet the needs of the underserved Chinese radiation therapy market, with the potential to significantly increase treatment capacity and improve patient outcomes [1][5] Product Impact - The Tomo C System, based on the helical TomoTherapy® platform, enables the treatment of an average of 95 patient fractions per day, significantly increasing the hospital's capacity to provide innovative and effective cancer care [5] - The system integrates helical imaging, advanced treatment planning, and centralized data management to facilitate fast, ultra-precise treatments, allowing more patients to receive care each day [5] Strategic Collaboration - Shandong Cancer Hospital and Institute, a top cancer care center in China, serves over 400,000 patients annually and collaborates with global leaders such as MD Anderson Cancer Center, reinforcing its commitment to innovation and excellence in cancer treatment [4] - The introduction of the Tomo C System expands Accuray's product portfolio in China and reinforces its commitment to providing advanced tools for precision radiotherapy [4][5] Leadership Perspective - Suzanne Winter, President and CEO of Accuray, emphasized the system's ability to treat a wide range of cancer types and its potential to meaningfully increase treatment capacity, enabling more patients to receive care daily [3] - Prof. Yu, President of Shandong Cancer Hospital, highlighted the transformative impact of the TomoTherapy platform and the Tomo C System's role in advancing precision radiotherapy and supporting the "Healthy China Initiative" [5]